Zacks Research Has Negative Outlook of CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Zacks Research lowered their Q1 2025 earnings per share estimates for Charles River Laboratories International in a research note issued on Wednesday, March 12th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.08 for the quarter, down from their prior estimate of $3.10. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.38 EPS, Q3 2025 earnings at $2.51 EPS, Q4 2025 earnings at $2.58 EPS, FY2025 earnings at $9.55 EPS, Q1 2026 earnings at $2.46 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.71 EPS, Q4 2026 earnings at $2.78 EPS and FY2026 earnings at $10.60 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period last year, the firm earned $2.46 earnings per share.

Other equities analysts have also recently issued research reports about the stock. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a report on Monday, March 3rd. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Finally, Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Stock Up 2.6 %

NYSE:CRL opened at $171.27 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a 50-day simple moving average of $167.74 and a 200 day simple moving average of $184.50. Charles River Laboratories International has a one year low of $150.79 and a one year high of $274.77. The company has a market capitalization of $8.76 billion, a price-to-earnings ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of CRL. Empirical Finance LLC lifted its stake in shares of Charles River Laboratories International by 4.2% in the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after purchasing an additional 53 shares during the last quarter. Fiduciary Financial Group LLC lifted its stake in shares of Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. M&T Bank Corp lifted its position in Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after acquiring an additional 66 shares during the last quarter. Finally, Cornerstone Investment Partners LLC lifted its position in Charles River Laboratories International by 3.7% during the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock worth $358,000 after acquiring an additional 69 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).